Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from GeneTether Therapeutics, Inc. ( (TSE:GTTX) ).
Rize Oncology, formerly GeneTether Therapeutics, has announced its rebranding to reflect a strategic pivot towards oncology, with a focus on soft tissue sarcoma. The company has licensed STS-201, a small molecule drug showing potential in treating soft tissue sarcoma and other cancers, aiming to address critical unmet medical needs and possibly qualify for Orphan Drug status. This shift is anticipated to enhance Rize’s market positioning and align its corporate identity with its mission to advance cancer treatments.
More about GeneTether Therapeutics, Inc.
GeneTether Therapeutics Inc., now rebranded as Rize Oncology, operates within the biotechnology industry with a new strategic focus on oncology, specifically targeting soft tissue sarcoma and other cancer treatments. The company has recently acquired STS-201, a promising small molecule drug candidate, marking its commitment to addressing unmet medical needs in this domain.
YTD Price Performance: 33.33%
Average Trading Volume: 7,600
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$4.11M
For detailed information about GTTX stock, go to TipRanks’ Stock Analysis page.
